$MRSN
Mersana Therapeutics, Inc. Stock $mrsn

$mrsn Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000162828022013191 Filed on May 09, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$2.036M	$11.00K
YoY Change	18409.09%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.78M	$7.210M
YoY Change	77.28%	45.95%
% of Gross Profit
Research & Development	$35.81M	$27.42M
YoY Change	30.61%	124.36%
% of Gross Profit
Depreciation & Amortization	$205.0K	$226.0K
YoY Change	-9.29%	-8.87%
% of Gross Profit
Operating Expenses	$48.59M	$34.62M
YoY Change	40.33%	101.82%
Operating Profit
YoY Change
Interest Expense	$724.0K	$93.00K
YoY Change	678.49%	5.68%
% of Operating Profit
Other Income/Expense, Net	-$706.0K	-$81.00K
YoY Change	771.6%	-137.16%
Pretax Income	-$47.26M	-$34.69M
YoY Change	36.23%	104.9%
Income Tax
% Of Pretax Income
Net Earnings	-$47.26M	-$34.69M
YoY Change	36.22%	104.97%
Net Earnings / Revenue	-2321.12%	-315390.91%
Basic Earnings Per Share	-$0.59	-$0.50
Diluted Earnings Per Share	-$0.59	-$0.50
COMMON SHARES
Basic Shares Outstanding	79.93M shares	68.99M shares
Diluted Shares Outstanding	79.93M shares	68.99M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$230.1M	$228.4M
YoY Change	0.73%	191.33%
Cash & Equivalents	$230.1M	$228.4M
Short-Term Investments
Other Short-Term Assets	$11.41M	$3.500M
YoY Change	226.09%	84.21%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$241.5M	$232.0M
YoY Change	4.1%	188.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.55M	$12.40M
YoY Change	17.34%	-12.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.247M	$3.520M
YoY Change	-36.16%	134.67%
Total Long-Term Assets	$16.80M	$15.96M
YoY Change	5.25%	2.3%
TOTAL ASSETS
Total Short-Term Assets	$241.5M	$232.0M
Total Long-Term Assets	$16.80M	$15.96M
Total Assets	$258.3M	$247.9M
YoY Change	4.18%	158.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.775M	$11.74M
YoY Change	-16.76%	155.28%
Accrued Expenses	$27.48M	$17.50M
YoY Change	57.04%	157.29%
Deferred Revenue	$16.58M	$3.976M
YoY Change	316.95%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$56.46M	$34.92M
YoY Change	61.7%	99.54%
LONG-TERM LIABILITIES
Long-Term Debt	$25.00M	$5.200M
YoY Change	380.77%	40.54%
Other Long-Term Liabilities	$389.0K	$318.0K
YoY Change	22.33%	-97.23%
Total Long-Term Liabilities	$25.39M	$5.518M
YoY Change	360.11%	-63.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$56.46M	$34.92M
Total Long-Term Liabilities	$25.39M	$5.518M
Total Liabilities	$117.7M	$49.97M
YoY Change	135.61%	52.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$497.7M	-$315.1M
YoY Change	57.94%
Common Stock	$638.3M	$513.1M
YoY Change	24.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$140.5M	$197.9M
YoY Change
Total Liabilities & Shareholders Equity	$258.3M	$247.9M
YoY Change	4.18%	158.51%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$47.26M	-$34.69M
YoY Change	36.22%	104.97%
Depreciation, Depletion And Amortization	$205.0K	$226.0K
YoY Change	-9.29%	-8.87%
Cash From Operating Activities	-$7.955M	-$27.02M
YoY Change	-70.56%	27.19%
INVESTING ACTIVITIES
Capital Expenditures	$329.0K	$114.0K
YoY Change	188.6%	75.38%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$329.0K	-$114.0K
YoY Change	188.6%	-100.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$60.39M	$472.0K
YoY Change	12695.34%	-624.44%
NET CHANGE
Cash From Operating Activities	-$7.955M	-$27.02M
Cash From Investing Activities	-$329.0K	-$114.0K
Cash From Financing Activities	$60.39M	$472.0K
Net Change In Cash	$52.11M	-$26.66M
YoY Change	-295.43%	1302.63%
FREE CASH FLOW
Cash From Operating Activities	-$7.955M	-$27.02M
Capital Expenditures	$329.0K	$114.0K
Free Cash Flow	-$8.284M	-$27.14M
YoY Change	-69.47%	27.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001442836
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3562403
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-38129
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Mersana Therapeutics, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	840 Memorial Drive
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2022Q1	dei	City Area Code CityAreaCode	617
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	498-0020
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177947000	USD
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96991298	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	230057000	USD
CY2022Q1	dei	Trading Symbol TradingSymbol	MRSN
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11413000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10951000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	241470000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	188898000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2549000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	1968000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12001000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12889000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2247000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2356000	USD
CY2022Q1	us-gaap	Assets Assets	258267000	USD
CY2021Q4	us-gaap	Assets Assets	206111000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9775000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12321000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27475000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28716000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16578000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3944000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2404000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2303000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	231000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	239000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	56463000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	47523000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10567000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11247000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	24702000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	24626000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25620000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	389000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	974000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	117741000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	84370000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73709056	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87073084	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87073084	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73709056	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	9000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2036000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	638254000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	572213000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-497737000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-450479000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	140526000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	121741000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	258267000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	206111000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35806000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27415000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12782000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7208000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	48588000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	34623000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	724000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	93000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-706000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-81000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-47258000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-34693000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47258000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-47258000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34693000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-34693000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79928591	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79928591	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68987857	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68987857	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	228087000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	764000	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	259000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4039000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-34693000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	197938000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	121741000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	96000	USD
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5485000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-47258000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	140526000	USD
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-47258000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-34693000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	205000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	226000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5485000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4039000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-194000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-38000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	462000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	37000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1366000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2524000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3415000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2159000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1251000	USD
CY2022Q1	mrsn	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	889000	USD
CY2021Q1	mrsn	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	415000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-579000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-299000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	38254000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-11000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7955000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27022000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	329000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	114000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-329000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-114000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	96000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	764000	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	259000	USD
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	76000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	230535000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	228751000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	457000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	189000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	531000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	33000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60394000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	472000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	52110000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26664000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	178425000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	255415000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	60000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	213000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-47300000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-34700000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-497700000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, management’s judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.</span></div>
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177947000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	230057000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	255094000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	228430000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	321000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	321000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	178425000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	230535000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	255415000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	228751000	USD
CY2022Q1	mrsn	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	9381000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27475000	USD
CY2021Q4	mrsn	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	8476000	USD
CY2022Q1	mrsn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	7569000	USD
CY2021Q4	mrsn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	7879000	USD
CY2022Q1	mrsn	Accrued Preclinical Expenses Current AccruedPreclinicalExpensesCurrent	4824000	USD
CY2021Q4	mrsn	Accrued Preclinical Expenses Current AccruedPreclinicalExpensesCurrent	3848000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3456000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7319000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1751000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	909000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	494000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	285000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28716000	USD
CY2022Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	400000	USD
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	25000000	USD
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25000000	USD
CY2022Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	388000	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	90000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	24702000	USD
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	700000	USD
CY2021Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	100000	USD
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	mrsn	Class Of Warrant Or Right Securities Called By Warrants Or Rights Number Issued ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued	129491	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.05
	mrsn	Contractual Life Of Warrants ContractualLifeOfWarrants	P10Y
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	39474	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9199512	shares
CY2022Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of the common stock are entitled to one vote for each share held.
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11524655	shares
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11524655	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9199512	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8342429	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.25
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1917634	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.05
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	26951	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.58
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	204371	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	12.74
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10028741	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.25
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10028741	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.25
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4307274	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.14
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.39
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.51
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	800000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5485000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4039000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5485000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4039000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.006
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y14D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y21D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.87
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.83
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11524655	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8600223	shares

Files In Submission

Name	View Source	Status
0001628280-22-013191-index-headers.html	Edgar Link	pending
0001628280-22-013191-index.html	Edgar Link	pending
0001628280-22-013191.txt	Edgar Link	pending
0001628280-22-013191-xbrl.zip	Edgar Link	pending
exhibit102.htm	Edgar Link	pending
exhibit103.htm	Edgar Link	pending
exhibit104.htm	Edgar Link	pending
exhibit105.htm	Edgar Link	pending
exhibit106.htm	Edgar Link	pending
exhibit31110-qfy2022q1.htm	Edgar Link	pending
exhibit31210-qfy2022q1.htm	Edgar Link	pending
exhibit32110-qfy2022q1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01a.jpg	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrsn-20220331.htm	Edgar Link	pending
mrsn-20220331.xsd	Edgar Link	pending
mrsn-20220331_cal.xml	Edgar Link	unprocessable
mrsn-20220331_def.xml	Edgar Link	unprocessable
mrsn-20220331_htm.xml	Edgar Link	completed
mrsn-20220331_lab.xml	Edgar Link	unprocessable
mrsn-20220331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRSN
Mersana Therapeutics, Inc. Stock $mrsn

2022 Q1 Form 10-Q Financial Statement

#000162828022013191 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRSN Mersana Therapeutics, Inc. Stock $mrsn

2022 Q1 Form 10-Q Financial Statement

#000162828022013191 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRSN
Mersana Therapeutics, Inc. Stock $mrsn